Single Ascending Dose Study of ALA-1000

NCT04122755 | Completed Phase 1 DMC FDA Drug

• 1 other identifier: A1-19-P01
• Study Type: interventional
• Target: 59
• Locations: 1 country
• Sites: 1

Brief Summary

An open-label study designed to evaluate the safety, tolerability, and pharmacokinetics of ALA-1000 in opioid-dependent subjects. To characterize the PK profile of ALA-1000 in 5 single ascending dose cohorts and a sixth cohort of single ALA-1000 after receiving buprenorphine sublingual films for 7 days.

Conditions

Opioid-use Disorder

Outcome Measures

Primary Outcomes (11)

• Incidence of AEs will be summarized by treatment overall, by severity, and by relationship to ALA-1000. Serious AEs and AEs leading to discontinuation of study drug will also be presented.

  Baseline (prior to dosing) through the End of Study (Day175), or Early termination

• Change of vital signs will be assessed in subjects receiving ALA-1000.

  Vital signs including blood pressure, pulse rate, respiration rate, pulse oximetry and temperature. Systolic and diastolic blood pressure will be assessed while supine and standing. Pulse oximetry will be monitored continuously for 24 hours post injection to assess for any signs/symptoms of respiratory depression.

  Baseline (prior to dosing) through the End of Study (Day175), or Early termination

• Chang of clinical laboratory assessments (biochemistry, hematology and urinalysis) will be assessed in subjects receiving ALA-1000.

  Samples will be collected for laboratory tests, including hematology, serum chemistry, urinalysis, serum/urine pregnancy test (conducted for females of childbearing potential only), and urine drug screen, to assess the safety of subjects.

  Baseline (prior to dosing) through the End of Study (Day175), or Early termination

• Change of ECG parameter of QTcF interval will be assessed in subjects receiving ALA-1000

  Baseline (prior to dosing) through the End of Study (Day175), or Early termination

• A standard physical examination will be performed to monitor the safety in subjects receiving ALA-1000

  The examination will include assessment of skin, head, ears, eyes, nose, throat, neck, thyroid, lungs, heart, cardiovascular, abdomen, lymph nodes, and musculoskeletal system/extremities.

  Baseline (prior to dosing) to the End of Study (Day175), or Early termination

• Injection site assessment will be conducted to monitor the safety in subjects receiving ALA-1000

  Injection site assessment including pain, tenderness, induration, erythema/redness, and swelling. If an infection develops at the injection site, the subject will be withdrawn from the study.

  From the end of ALA-1000 injection through the End of Study (Day175), or Early termination

• Concomitant medications will be reviewed and documented to monitor the safety in subjects receiving ALA-1000

  The medication name, dose, frequency, date, and indication for use must be recorded

  Prior to dosing through the End of Study (Day175), or Early termination

• AUC (area under the plasma concentration-time curve) for subjects receive ALA-1000 injection

  Prior to ALA-1000 injection through the End of Study (Day175), or Early termination

• Cmax (maximum observed plasma concentration) for subjects receive ALA-1000 injection

  Prior to ALA-1000 injection through the End of Study (Day175), or Early termination

• Tmax (time to maximum concentration) for subjects receive ALA-1000 injection

  Prior to ALA-1000 injection through the End of Study (Day175), or Early termination

• t1/2 (time to half plasma concentration) for subjects receive ALA-1000 injection

  Prior to ALA-1000 injection through the End of Study (Day175), or Early termination

Secondary Outcomes (3)

• Change of opioid withdrawal symptoms will be assessed using Clinical Opiate Withdrawal Scale (COWS) for subjects receive ALA-1000 injection

  Baseline (prior to dosing) through the End of Study (Day175), or Early termination

• Change of suicidal ideation will be assessed using Columbia-Suicide Severity Rating Scale (C-SSRS) for subjects receive ALA-1000 injection

  Screening through the End of Study (Day175), or Early termination

• Assessment of the abstinence by urine toxicology results negative for opioids in subjects received ALA-1000 injection.

  Screening through the End of Study (Day175), or Early termination

Study Arms (6)

Cohort1

EXPERIMENTAL

Subjects receive a single subcutaneous injection of 1-fold ALA-1000 dose (first in human dose).

Drug: ALA-1000

Cohort2

EXPERIMENTAL

Subjects receive a single subcutaneous injection of 2-fold ALA-1000 dose

Drug: ALA-1000

Cohort3

EXPERIMENTAL

Subjects receive a single subcutaneous injection of 4.7-fold ALA-1000 dose

Drug: ALA-1000

Cohort4

EXPERIMENTAL

Subjects receive a single subcutaneous injection of 9.4-fold ALA-1000 dose

Drug: ALA-1000

Cohort5

EXPERIMENTAL

Subjects receive a single subcutaneous injection of 18.8-fold ALA-1000 dose

Drug: ALA-1000

Cohort6

EXPERIMENTAL

Subjects receive a single subcutaneous injection of 18.8-fold ALA-1000 dose after 7 days of buprenorphine sublingual film dosing

Drug: ALA-1000; Drug: buprenorphine sublingual film

Interventions

ALA-1000 DRUG

Blood sample for PK analysis are collected before and post single injection of ALA-1000 (Day1) according to the schedule of procedures. Subjects remain in the residential phase through Day21 for safety assessment.

Also known as: Depot Buprenorphine Formulation

Cohort1; Cohort2; Cohort3; Cohort4; Cohort5; Cohort6

buprenorphine sublingual film DRUG

ALA-1000 injection after 7 days of buprenorphine sublingual film dosing. Blood sample for PK analysis are collected before and post sublingual buprenorphine dosing on Day-1

Cohort6

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Competent to provide informed consent.
• Voluntarily provide informed consent and Health Insurance Portability and Accounting Act (HIPAA) Authorization prior to any procedures or evaluations performed specifically for the sole purpose of the study.
• Male or female between 18 to 65 years of age inclusive at the screening visit.
• Meets DSM-5 criteria for Opioid Use Disorder (OUD) and is seeking treatment of OUD.
• Body Mass Index (BMI) ≥ 18 and ≤ 35 kg/m2 at screening visit.
• Female subjects of childbearing potential must agree to use a reliable method of birth control (e.g., total abstinence, condom and spermicide, intrauterine device (IUD), oral contraception which has been stable for 30 days) and at least 120 days after stopping the investigational product.
• Agree to withdraw from opiates for at least 12 hours prior to admission to clinical unit.
• Agree not to take any buprenorphine product (other than ALA-1000 and buprenorphine sublingual films during tolerability/induction period) during the study.

You may not qualify if:

• History or presence of a significant medical disease or disorder which, in the opinion of the investigator, increases the risk of the study drug or may confound the interpretation of study measures, as confirmed by screening laboratory results.
• Clinically significant abnormal findings on physical examination, vital signs, or Electrocardiogram (ECG). Defined as having a QTc (Fridericia) interval \> 470 msec or any other clinically significant abnormalities at screening, check-in, or prior to administration of ALA-1000.
• Pregnant or lactating.
• History of suicidal behavior in the past 1 year or current suicidal ideation as per investigator judgement.
• Currently meets Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria for substance use disorder, moderate or severe for any substance other than opioids, caffeine, or nicotine.
• Currently meets criteria for any unstable psychiatric disorder, including schizophrenia, schizoaffective, bipolar disorder (depression and stable bipolar disorder are not excluded if condition has been stable for at least 60 days).
• Current diagnosis of Acquired Immune Deficiency Syndrome (AIDS) as confirmed by Western Blot and viral load laboratory results.
• Acute active Hepatitis B or C as evidenced by positive serology and Aspartate aminotransferase (AST)/ Alanine aminotransferase (ALT) \>2 upper limit of normal (ULN)
• History of blood donation in excess of 450 mL within 30 days prior to Visit 1.
• Received treatment with an investigational drug or device within 90 days prior to Visit 1.
• Use of strong inhibitors or inducers of cytochrome P450 3A4 (CYP3A4) within 30 days prior to Visit 1.
• Use of any new medication, vitamins, or supplements within 7 days prior to Visit.
• Hypersensitivity or allergy to buprenorphine or other opioids which, in the opinion of the investigator, would compromise subject safety.

Sponsors & Collaborators

• Alar Pharmaceuticals Inc.: lead

Study Sites (1)

Innovative Clinical Research

Miami, Florida, 33016, United States

Location

MeSH Terms

Conditions

Opioid-Related Disorders

Condition Hierarchy (Ancestors)

Narcotic-Related Disorders; Substance-Related Disorders; Chemically-Induced Disorders; Mental Disorders

Study Officials

• Erin Tireman

  Innovative Clinical Research

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: October 8, 2019
• First Posted: October 10, 2019
• Study Start: September 16, 2019
• Primary Completion: May 3, 2021
• Study Completion: May 3, 2021
• Last Updated: December 30, 2021

Record last verified: 2021-12

Locations

US (1)